List of Excipients in Branded Drug DIPHENOXYLATE HCL AND ATROPINE SULFATE

Generic Drugs Containing DIPHENOXYLATE HCL AND ATROPINE SULFATE

Company	Ingredient	NDC	Excipient
Stat Rx USA	diphenoxylate hcl and atropine sulfate	16590-080	LACTOSE MONOHYDRATE
Stat Rx USA	diphenoxylate hcl and atropine sulfate	16590-080	MAGNESIUM STEARATE
Stat Rx USA	diphenoxylate hcl and atropine sulfate	16590-080	STARCH, CORN
Stat Rx USA	diphenoxylate hcl and atropine sulfate	16590-080	SUCROSE

What are the Most Frequently-Used Excipients in DIPHENOXYLATE HCL AND ATROPINE SULFATE?

# Of NDCs	Excipient
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	STARCH, CORN
1	SUCROSE

Diphenoxylate HCl and Atropine Sulfate Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Diphenoxylate hydrochloride and atropine sulfate is an established immediate-release antidiarrheal combination with limited active-ingredient patent protection and substantial opportunity for differentiated excipient systems. The commercial focus is unlikely to be basic generic tablets. Higher-value opportunities include alcohol-free oral solutions, sugar-free and taste-masked liquids, unit-dose packaging, pediatric-risk-controlled presentations, and manufacturing platforms that improve content uniformity at the very low atropine dose.

What is the diphenoxylate HCl and atropine sulfate drug product?

Diphenoxylate hydrochloride and atropine sulfate is an oral combination used as adjunctive therapy for acute or chronic diarrhea. The standard tablet contains:

Component	Typical strength per tablet	Function
Diphenoxylate hydrochloride	2.5 mg	Antidiarrheal opioid derivative
Atropine sulfate	0.025 mg	Deterrent against deliberate diphenoxylate misuse
Dosage form	Immediate-release tablet	Oral administration

The combination is commonly known as Lomotil. Diphenoxylate is related pharmacologically to opioid antidiarrheals, while the low atropine content produces anticholinergic effects at excessive intake. The product is federally classified as a Schedule V controlled substance in the United States because of its diphenoxylate content and atropine combination.[1]

FDA labeling warns against use in children younger than 6 years and identifies risks including respiratory depression, severe dehydration, toxic megacolon, anticholinergic reactions, and central nervous system effects.[1] These restrictions materially affect pediatric positioning, flavor strategy, dosing devices, and promotional claims.

What excipients are used in diphenoxylate-atropine tablets?

Public product labels for generic diphenoxylate hydrochloride and atropine sulfate tablets identify conventional immediate-release excipients. Depending on the manufacturer, these may include lactose, starch, microcrystalline cellulose, povidone, crospovidone, talc, magnesium stearate, colloidal silicon dioxide, and coating materials.[2]

The excipient system has four technical priorities:

1. Accurate distribution of atropine sulfate at 0.025 mg per tablet.
2. Rapid and reproducible disintegration.
3. Physical stability of a low-dose, two-active blend.
4. Acceptable tablet robustness without excessive compression force.

Atropine represents only about 1% of the nominal diphenoxylate hydrochloride strength by mass. Direct blending can therefore create content-uniformity risk, particularly when batch sizes are large or particle-size distributions differ between active ingredients.

Which excipient risks are most important?

Technical risk	Commercial consequence	Preferred mitigation
Poor atropine distribution	Content-uniformity failures and batch rejection	Ordered mixing, geometric dilution, carrier granulation, in-process sampling
Segregation during compression	Tablet-to-tablet potency variability	Matched particle size, controlled density, low-transfer handling
Lactose intolerance concerns	Reduced market access for some patients	Lactose-free formulation
Sugar in liquid products	Limited suitability for diabetic patients	Sorbitol, xylitol, glycerin, or other non-sucrose systems
Bitter or medicinal taste	Low adherence to oral liquids	Polymer coating, ion-exchange resin, sweetener and flavor system
Excessive tablet hardness	Slow disintegration and dissolution	Optimized superdisintegrant and lubricant levels
Moisture sensitivity	Stability loss or altered flow	Moisture-barrier packaging and controlled water activity

Excipient selection must be assessed against the FDA inactive-ingredient database, the finished-product label, USP requirements, and the intended route and dosage form.[3]

What formulation patents protect diphenoxylate HCl and atropine sulfate?

The core combination is old and is unlikely to have meaningful remaining composition-of-matter protection. The principal commercial barrier is regulatory execution rather than active-ingredient patent exclusivity.

Potentially protectable subject matter includes:

• Taste-masked oral solutions.
• Sustained-release or modified-release products.
• Low-dose atropine premixes.
• Multiparticulate or sprinkle formulations.
• Unit-dose liquid containers.
• Tamper-evident or abuse-deterrent delivery systems.
• Improved manufacturing processes for atropine content uniformity.
• Stabilized liquid formulations.
• Pediatric dosing systems, although labeling restrictions remain decisive.

A new formulation patent would need a defensible technical distinction and clinically or analytically meaningful performance. A claim directed only to routine excipient substitution is vulnerable to obviousness and written-description challenges.

When does diphenoxylate-atropine lose exclusivity?

The active ingredients have been available for decades, and the conventional immediate-release tablet is generally treated as an established generic product rather than a patent-protected innovation. New entrants therefore usually pursue an ANDA referencing the FDA-listed reference product rather than a 505(b)(2) application.

The practical exclusivity position is:

Exclusivity category	Assessment
New chemical entity exclusivity	Expired
Core composition patent	Expired or commercially irrelevant because of age
Conventional tablet exclusivity	Generally unavailable
Formulation patents	Possible only for later-developed products
Orphan exclusivity	Not applicable to the standard product
Pediatric exclusivity	No general current exclusivity basis
Biosimilar exclusivity	Not applicable

Exact Orange Book listings, patent certifications, and discontinued-product status must be confirmed against the current FDA database before filing or acquisition decisions.[4]

What is the Orange Book status of diphenoxylate-atropine?

FDA Orange Book analysis should distinguish the reference-listed drug from current generic approvals. The relevant regulatory questions are whether an NDA remains listed, whether the reference product is marketed, whether any patents or exclusivity codes remain, and whether the proposed product can rely on an active reference listing.

For a conventional tablet or oral solution, the likely pathway is an ANDA if the proposed product matches the reference product in active ingredients, strength, dosage form, route, labeling basis, and applicable performance requirements. An applicant must evaluate:

• Product-specific bioequivalence requirements.
• Dissolution specifications.
• Inactive-ingredient differences.
• Controlled-substance registration and handling.
• Labeling requirements for misuse, overdose, dehydration, and pediatric use.
• Patent certifications under section viii or Paragraph IV, if applicable.

A Paragraph IV challenge is commercially relevant only if the Orange Book identifies an unexpired patent covering the reference product or its use. For an old diphenoxylate-atropine tablet, the higher probability is that no core patent blocks a standard ANDA. A later formulation patent could still create risk for a differentiated liquid, modified-release product, or abuse-deterrent system.

What excipient strategies create commercial opportunities?

1. Sugar-free, alcohol-free oral solution

An oral solution can address patients who cannot swallow tablets and institutional settings that need flexible dosing. The formulation must control:

• Solubility and concentration of both active ingredients.
• pH-dependent stability.
• Preservative performance.
• Sedimentation or crystallization risk.
• Dose-measurement accuracy.
• Taste and mouthfeel.

A sugar-free system based on sorbitol, glycerin, or a mixed polyol platform could target diabetes-conscious consumers and hospitals. The product should avoid unnecessary ethanol, particularly for pediatric-risk-sensitive and institutional use.

Taste masking is difficult because diphenoxylate and atropine both contribute undesirable sensory characteristics. A combination of sweeteners, high-intensity flavor, viscosity control, and potentially resin-based complexation may be required. Resin complexation must not reduce bioavailability or create unacceptable release variability.

2. Lactose-free tablets

A lactose-free tablet is a relatively low-cost differentiation strategy. The product can replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or starch-based systems. The commercial benefit is strongest where pharmacies or hospital formularies prefer a broader excipient profile.

This strategy is unlikely to support strong patent protection by itself. Its value lies in procurement, patient preference, and supply-chain differentiation.

3. Improved low-dose content uniformity

The low atropine dose creates a manufacturing opportunity. A proprietary premix can distribute atropine sulfate onto a controlled carrier before final blending. Candidate carriers include microcrystalline cellulose, mannitol, lactose substitutes, or spray-dried composite excipients.

A defensible process patent could cover:

• Carrier particle-size range.
• Ordered mixing sequence.
• Atropine-to-carrier ratio.
• Granulation endpoint.
• Blend uniformity criteria.
• Compression and segregation controls.

The business case is stronger when the process reduces rejected batches, permits larger-scale production, or supports a smaller tablet.

4. Orally disintegrating or mini-tablet formats

An orally disintegrating tablet could improve administration for adults with swallowing difficulties. The formulation would need fast disintegration, low friability, and robust taste masking.

A mini-tablet may offer dose flexibility, but the controlled-substance status and atropine exposure risk make dose manipulation a regulatory concern. Claims should focus on adult administration and should not imply pediatric suitability where FDA labeling does not support it.

5. Unit-dose liquid packaging

Unit-dose cups, oral syringes, and tamper-evident pouches may have more immediate commercial value than a new tablet technology. Hospitals and long-term-care facilities value dose accuracy, reduced cross-contamination, and simplified controlled-substance reconciliation.

Packaging patents may cover container geometry, closure systems, dose-measurement features, or tamper evidence. These rights would protect the delivery system rather than the drug formulation.

What manufacturing and intellectual-property barriers affect entry?

The largest technical barrier is not synthesis. It is reliable finished-product control at the low atropine dose.

Manufacturing controls should address:

• Separate weighing and verification of atropine.
• Validated premixing or granulation.
• Blend uniformity across beginning, middle, and end of discharge.
• Dust containment and operator exposure.
• In-process tablet weight and hardness.
• Assay and content uniformity for both actives.
• Dissolution of the immediate-release dosage form.
• Stability under commercial packaging conditions.

Controlled-substance manufacturing also requires DEA registration, inventory controls, security procedures, recordkeeping, and distribution controls.[5]

For liquid products, the principal risks are preservative efficacy, microbial control, container compatibility, and dose-measurement error. A proprietary excipient system has commercial value only if it produces measurable stability, palatability, manufacturability, or bioequivalence advantages.

Which companies are challenging or competing with diphenoxylate-atropine?

Competition is primarily generic and includes manufacturers and distributors of diphenoxylate hydrochloride and atropine sulfate tablets or oral solutions. The competitive set also includes alternative antidiarrheals:

Product	Active ingredient	Competitive position
Diphenoxylate-atropine	Diphenoxylate HCl plus atropine sulfate	Prescription antidiarrheal; controlled substance
Loperamide	Loperamide HCl	Widely available; generally stronger retail presence
Bismuth subsalicylate	Bismuth subsalicylate	OTC alternative for selected diarrhea indications
Racecadotril	Racecadotril	Used in certain non-U.S. markets
Oral rehydration products	Electrolytes and glucose	Treat dehydration rather than intestinal motility directly

Loperamide is the most important commercial comparator in many markets because it is widely available and does not carry the same prescription-controlled-substance positioning. Diphenoxylate-atropine can compete where clinicians prefer a prescription product, where diarrhea is persistent, or where formulary protocols specify it.

What patent litigation and settlement risks exist?

There is no obvious basis for assuming active litigation around the old conventional combination without a current court and Orange Book search. The main litigation scenarios would involve:

1. A later entrant claiming a new liquid, abuse-deterrent formulation, or modified-release system.
2. A Paragraph IV challenge to a formulation patent.
3. Trade-secret litigation involving a low-dose blending process.
4. Patent disputes over taste masking, resin complexes, or unit-dose packaging.
5. Product-liability litigation involving pediatric administration, overdose, respiratory depression, or anticholinergic toxicity.

Settlement agreements are more likely in connection with later-developed formulation patents than with the basic tablet. Any settlement should be reviewed for launch dates, authorized-generic provisions, supply commitments, patent licenses, and restrictions on dosage forms.

How strong is the patent estate for diphenoxylate HCl and atropine sulfate?

The conventional product has a weak patent moat but a potentially useful formulation-development platform.

Estate category	Relative strength
Active ingredients	Very weak because of age
Standard immediate-release tablet	Weak
Liquid stability system	Moderate if supported by unexpected results
Taste masking	Moderate, depending on claims and prior art
Low-dose manufacturing process	Moderate if process data are strong
Abuse-deterrent delivery	Potentially stronger but commercially and regulatorily complex
Packaging and unit-dose systems	Narrow, implementation-dependent

The strongest investment case is a differentiated product that combines regulatory simplicity with a practical procurement benefit. A new formulation should avoid relying on a single narrow patent claim.

What generic launch scenarios exist?

Standard ANDA tablet

This is the lowest-cost pathway but also the most commoditized. Price erosion, multiple approved suppliers, and pharmacy substitution can limit returns.

Differentiated oral solution

This has a larger technical burden but can support institutional sales, swallowing-difficulty use, and dosing flexibility. It may also face fewer direct competitors than tablets.

505(b)(2) reformulation

A 505(b)(2) strategy could be relevant for a genuinely novel dosage form, delivery system, or modified-release product. It would carry greater clinical, regulatory, and patent risk than an ANDA.

Hospital and long-term-care product

Unit-dose packaging, oral syringes, barcode-ready labels, and controlled-substance reconciliation may create a procurement advantage without requiring a novel active ingredient.

How does diphenoxylate-atropine compare with loperamide?

Factor	Diphenoxylate-atropine	Loperamide
Prescription status in the U.S.	Yes	OTC and prescription forms exist
Controlled substance	Schedule V	Not federally scheduled
Atropine exposure	Present	Absent
Retail accessibility	Lower	Higher
Formulation opportunity	Liquids, unit doses, taste masking	Broader OTC product formats
Safety messaging	Strong focus on misuse, overdose, pediatric risk	Strong focus on cardiac risk at excessive doses
Patent opportunity	Mainly formulation and process	More active product and formulation landscape

The combination’s commercial opportunity depends on clinical channel selection rather than mass-market consumer positioning.

Key Takeaways

• Diphenoxylate HCl and atropine sulfate is an old combination with little likely value in core active-ingredient patent protection.
• The most attractive excipient opportunities are sugar-free, alcohol-free liquids; lactose-free tablets; taste-masked formulations; and unit-dose packaging.
• Atropine’s very low dose creates a meaningful blend-uniformity and segregation-control opportunity.
• A conventional tablet is likely to face intense generic price competition.
• An ANDA is the likely route for a standard product; a 505(b)(2) pathway may apply to a genuinely novel dosage form.
• Biosimilar risk is irrelevant because this is a small-molecule combination, not a biologic.
• Formulation patents require technical data showing stability, dissolution, bioavailability, palatability, or manufacturing advantages.
• FDA labeling restrictions, controlled-substance requirements, and pediatric safety concerns limit certain excipient and marketing strategies.

FAQs

Can diphenoxylate-atropine be formulated as a pediatric liquid?

A liquid dosage form is technically feasible, but FDA labeling restricts use in children younger than 6 years and requires prominent safety controls. A pediatric-oriented commercial strategy must therefore distinguish administration convenience from a pediatric indication.

Is atropine sulfate a preservative in the formulation?

No. Atropine sulfate is an active ingredient in the combination and is included primarily to discourage excessive diphenoxylate use through anticholinergic effects.

Does a sugar-free diphenoxylate-atropine product require a new patent?

No. Sugar removal alone generally does not require patent protection and may be pursued through an ANDA if the product meets applicable sameness and bioequivalence requirements. Patentability would depend on an unexpected technical result.

Can a new excipient create a 505(b)(2) product?

A new excipient may contribute to a 505(b)(2) strategy, but excipient novelty alone does not guarantee eligibility. The dosage form must have a meaningful difference from the listed reference product and require reliance on FDA findings or additional data.

Is a biosimilar application available for diphenoxylate-atropine?

No. Diphenoxylate hydrochloride and atropine sulfate are small-molecule active ingredients. The relevant generic pathway is typically an ANDA, with a 505(b)(2) application potentially available for certain reformulations.

References

1. U.S. Food and Drug Administration. (2011). Lomotil (diphenoxylate hydrochloride and atropine sulfate) tablets prescribing information.
2. DailyMed. (n.d.). Diphenoxylate hydrochloride and atropine sulfate tablet labels. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. U.S. Drug Enforcement Administration. (n.d.). Controlled substance schedules and requirements for Schedule V substances.